




RealRate

PHARMACEUTICAL 2013

Oncotelic Therapeutics Inc
Rank 127 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Oncotelic Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 195%, being 25% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	5,243
Cost of Goods Sold	0
Intangible Assets	191
Liabilities, Current	901
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	15
Other Liabilities	0
Other Net Income	-7.0
Other Revenues	156
Property and Equipment	13
Research and Development	3,523
Selling, General and Administrative Expense	4,690

Output Variable	Value in 1000 USD
Assets	5,447
Liabilities	901
Expenses	8,228
Revenues	156
Stockholders Equity	4,546
Net Income	-8,079
Comprehensive Net Income	-8,079
BaseVar	7,370
ECR before Limited Liability	58%
Economic Capital Ratio	195%